The SHFJ is a research center dedicated to molecular and functional non-invasive imaging for clinical and preclinical research in oncology, neurology, neurodegenerative disease and psychiatry. The facility includes a nuclear medicine unit and is located in Orsay's Hospital area (near Paris).
<div class="ExternalClass0CEECC93DD5C417A9817D8E54EA099C7"><p>Molecular Imaging Research Center is a preclinical research installation created by the CEA and INSERM. This installation, consists of a group of platforms dedicated to the development of animal models pertinent to human diseases.</p></div>
NeuroSpin is a research center built to develop and validate neuroimaging using ultra-high Magnetic Field headed by Dr. Denis Le Bihan, a Member of the French Academy of Sciences. It was opened on January 1st 2007. The center is recognized as a large infrastructure, for biomedical imaging, such as the CERN in Genève. It is a shared imaging facility with unique imaging devices,. An 11.7T MRI scanner for human will be installed in 2016, one of the first in the world.
The Institute of Biomedicale Imaging take part in three projects: CATI, INUMAC project and Human Brain Project.
Toutes les faits marquants de l'I²BM
The M-CUBE research project is coordinated by Aix Marseille University (AMU) and led by the Fresnel Institute and the Center for Magnetic Resonance in Biology and Medicine (CRMBM). M-CUBE has been selected by the European Commission and is funded for 4 years from the 1st of January, 2017.
The group of Julien Flament is working on a new MRI modality, called CEST for Chemical Exchange Saturation Transfer, allowing in vivo mapping of some brain metabolites with a good spatial resolution. In the framework of a translational project funded by ANR (HDeNERGY project).
The psychiatry team of the clinical research UNIACT Lab at NeuroSpin, have published a study comparing with multimodal MRI two very frequent psychiatric conditions: high-functioning autism (also known as Asperger's syndrom) and schizophrenia.
The group of Marc Dhenain (MIRCen) has developed an MRI microscopy technique that can track in vivo the fate of amyloid plaques. This technique was used to characterize an immunotherapy targeting specific forms of amyloid (called protofibrillar). The article, published in collaboration with Sanofi, demonstrates an effective partnership between the CEA and industrial partners.
Recent work from the IMIV research lab suggests that tumor heterogeneity measured in vivo using PET images actually reflects the biological heterogeneity as measured ex vivo using pathological slides.
The group of Julien Valette (MIRCen) has developed, in the framework of a project funded by the European Research Council (ERC), a strategy to quantify some of the morphological characteristics of neurons and astrocytes, as published in PNAS in May 2016.
Two researchers of Neurospin have just revealed that the brain possesses a network of cerebral areas involved in the high-level mathematical as in the simplest arithmetic operations.
For the first time in human, a study proves that microglial activation seems to play a protective role in the clinical progression of the disease at these early stages of Alzheimer's disease.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.